Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

A Year to Remember: Dr. Jinoos Yazdany Presents the 2020 Clinical Research Review

Jason Liebowitz, MD, FACR  |  December 7, 2020

ACR Convergence 2020—2020 is a year that will not soon be forgotten—for many reasons. But even amidst a pandemic, notable advances in clinical rheumatology are a silver lining for the year. During the ACR Convergence 2020 Clinical Year in Review session, Jinoos Yazdany, MD, MPH, Alice Betts Endowed Professor and chief of rheumatology, Zuckerberg San Francisco General Hospital, University of California, San Francisco, discussed the highlights of these past 12 months and the ways in which numerous studies and discoveries will shape treatment changes in years to come.

Dr. Yazdany

TULIP-2 Results
With regard to systemic lupus erythematosus, Dr. Yazdany discussed a phase 3, randomized, controlled trial of anifrolumab, a human monoclonal antibody to type 1 interferon receptor, published this year.1 As readers may recall, a prior study involving anifrolumab (the Treatment of Uncontrolled Lupus via the Interferon pathway [TULIP] 1 study) did not show a significant effect on the primary end point of the Systemic Lupus Erythematosus Responder Index (SRI) 4, which is a composite of changes in three scales.2 This was disappointing because a phase 2 trial of this medication had shown promising results.3

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

However, in the TULIP 2 study, the authors used the British Isles Lupus Assessment Group (BILAG) based Composite Lupus Assessment (BICLA) as the primary endpoint to evaluate more than 360 patients with moderate or severe active lupus. Patients were randomized to receive anifrolumab or placebo, and those with severe renal or central nervous system involvement were excluded from the study. Whereas SRI-4 requires complete resolution within a particular item to register change and, therefore, does not capture partial improvements, the BICLA can register partial and complete improvement within an organ system, noted the authors.

The TULIP 2 study showed 48% of patients who received a monthly administration of anifrolumab had a BICLA response, compared with 31.5% in the placebo group.1

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Yazdany said these studies indicate that trial endpoints of lupus studies can make a big difference, and it remains challenging to identify which endpoints to use. Also, large trials with years of endpoint scrutiny and planning are needed to identify the optimal treatments for lupus patients.

Practically speaking, the TULIP trials also indicate that—if approved by the U.S. Food & Drug Administration—anifrolumab may become a treatment option for patients with active lupus who do not have severe renal or central nervous system disease.

Tapering Glucocorticoids
Next, Dr. Yazdany discussed the theme of optimizing glucocorticoid dosing and safety in the treatment of rheumatologic diseases.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ACR ConvergenceConditionsMeeting ReportsResearch Rheum Tagged with:ACR Convergence 2020anifrolumabaxial spondyloarthritis (SpA)Clinical researchCOVID-19GlucocorticoidsLupusrituximabVasculitis

Related Articles

    Anifrolumab Promising for Sustained Low Disease Activity in Patients with Lupus

    May 5, 2022

    ACR CONVERGENCE 2021—Using pooled data from the TULIP-1 and TULIP-2 clinical trials, researchers set out to identify whether more patients with systemic lupus erythematosus (SLE) being treated with anifrolumab achieved a low disease activity state than patients with SLE who received placebo.1-3 An analysis of the data was presented at ACR Convergence 2021 by Eric…

    Case Report: Hydralazine-Induced ANCA-Associated Vasculitis

    February 16, 2021

    Hydralazine has been in use as a treatment for hypertension, most notably in heart failure patients, since 1951.1 The drug is a known cause of autoimmune disease, most specifically hydralazine-induced lupus.  Hydralazine-induced lupus occurs in 7–13% of those taking the medication.2-4 It often presents with constitutional symptoms, arthritis/arthralgias, cutaneous lesions, sero­sitis, myalgias and/or hepatomegaly. Features…

    Vasculitis Guidelines in Focus, Part 2: ANCA-Associated Vasculitis

    September 9, 2021

    Sharon Chung, MD, MAS, discusses specific recommendations for the treatment and management of ANCA-associated vasculitis from the latest ACR Guideline.

    ACR Winter Rheumatology Symposium: Tips for ANCA Testing

    May 1, 2013

    How to select the correct testing method and interpret conflicting results from antineutrophil cytoplasmic antibody tests

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences